GALECTIN THERAPEUTICS INC — Director's Dealing 2016

Apr 21, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2016-04-19

Reporting Person: CZIRR JAMES C (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-04-19	Common Stock	S	33100	$1.7005	Disposed	3271909	Indirect
2016-04-20	Common Stock	S	11212	$1.5922	Disposed	3260697	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	886630	Direct
Common Stock	179232	Indirect

Footnotes

F1: Reflects weighted average price. Range of prices were between $1.69 and $1.715. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

F2: Reflects weighted average price. Range of prices were between $1.55 and $1.62. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

F3: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein.